News - Markets & Marketing, Biosimilars

Filter

Popular Filters

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Lucrative biosimilars space to erode biologics market from 2019

Lucrative biosimilars space to erode biologics market from 2019

11-06-2014

The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market…

BiosimilarsBiotechnologyGlobalMarkets & MarketingRegulation

European and Japanese generics groups view opportunities on biosimilars

European and Japanese generics groups view opportunities on biosimilars

29-05-2014

The European Generic Medicines Association (EGA) participated in several meetings with Japanese government…

BiosimilarsEuropeGenericsJapanMarkets & MarketingRegulation

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar

07-05-2014

Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

EGA president seeks partnership with Italian government on generics and biosimilars

09-04-2014

The president of the European Generic Medicines Association (EGA), Nick Haggar, attended the Stati Generali…

BiosimilarsEuropeGenericsItalyMarkets & MarketingPolitics

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

EGA calls for removal of barriers to competition and free trade for generics

EGA calls for removal of barriers to competition and free trade for generics

19-03-2014

The European Union must remove barriers to competition and free trade by introducing common sense reforms…

BiosimilarsEuropeGenericsMarkets & MarketingPatentsRegulation

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

30-01-2014

The imminent entry of several companies, including big pharma, small biotech and generic participants,…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesEuropeHospiraJohnson & JohnsonMarkets & MarketingNorth AmericaRemicadeUSA

Biocon introduces biosimilar trastuzumab for breast cancer in India

20-01-2014

India-based biotech firm Biocon (BSE: 532523) has introduced Canmab, a biosimilar trastuzumab, for the…

BioconBiosimilarsIndiaMarkets & MarketingOncologytrastuzumab

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

US FTC rescheduled workshop on state regulations and naming conventions set for February

31-12-2013

The US Federal Trade Commission announced its one-day public workshop on competition and follow-on biologics,…

BiosimilarsGenericsMarkets & MarketingNorth AmericaRegulationUSA

Rapid uptake of rheumatoid arthritis biosimilars expected in Brazil and Mexico

19-12-2013

Biosimilars will be quickly acquired and used in public health institutions in the treatment of patients…

Anti-Arthritics/RheumaticsBiosimilarsBrazilGenericsMarkets & MarketingRegulationSouth America

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

17-12-2013

US biotech major Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEuropeMarkets & MarketingSamsung Bioepis

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

07-12-2013

Key clinical, corporate and regulatory events affecting the biosimilar industry have been identified…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraMarkets & MarketingRegulationRemsima

Avesthagen in deal with Elpen for biosimilar Aranesp in parts of Europe

21-11-2013

Avesthagen Pharma AG, a unit of India’s Avesthagen Ltd, has signed an agreement with Greek life sciences…

AmgenAranespAvdespAvesthagenBiosimilarsElpen PharmaceuticalsEuropeMarkets & MarketingNephrology and Hepatology

Teva updates on Lonquex and Granix launches

Teva updates on Lonquex and Granix launches

18-11-2013

Israel-based Teva Pharmaceutical Industries announced two significant additions to its global oncology…

balugrastimBiosimilarsEuropeGenericsLonquexMarkets & MarketingNorth AmericaOncologyRegulationTeva Pharmaceutical Industries

Formycon set to exploit biosimilars opportunities, says analyst

08-11-2013

Germany-based Formycon AG is preparing to exploit the emerging opportunity for biosimilars, according…

BiosimilarsFinancialFormyconMarkets & Marketing

EGA views future for generics and biosimilars in Europe

EGA views future for generics and biosimilars in Europe

14-10-2013

The European Generic medicines Association (EGA) recently launched its industrial policy vision for the…

BiosimilarsEuropeGenericsMarkets & MarketingRegulation

Biosimilars uptake likely more rapid in USA than in Europe

10-10-2013

The US drug channel is likely to exhibit a higher acceptance of biosimilars, copy versions of biological…

BiosimilarsEuropeMarkets & MarketingNorth AmericaPricing

Back to top